Details For Selected Brain Tumor Treatment

Sponsored By

Please Click On The Above Banner For More Details

Last updated refers to the date when our listing for each treatment was last updated.
ID is our internal ID - starting with VT.
Min Karnofsky is a general guide to how well you have to function to use this treatment
For trials that also have a NCT number, you can click that number to pop up the listing from the clinicaltrials.gov website.

Back to New Treatments List



		Treatment Name:		A Randomized Phase II Trial of Bevacizumab With Irinotecan or Bevacizumab With Temozolomide in Recurrent Glioblastoma

		Keywords:		Irinotecan, Bevacizumab, Temozolomide

		Phase:		Phase 2

		Treatment ID#s:		VT1852 RTOG0625

		Age Group:		Adults Only

		Min Karnofsky Score:		70: Cares for self, unable to perform normal activity or to do active work

		Conditions:		Newly Diagnosed: N Recurrent: Y Prior Surgery is Allowed Prior Radiation is Allowed Prior Chemotherapy is Allowed Recurrent Glioblastoma or Gliosarcoma

		Last Updated:		04/15/2008

		Tumor Types:		Glioblastoma Multiforme Gliosarcoma


		Comments:		Patients will be assigned to one of two arms: Bevacizumab, a humanized monoclonal antibody against VEGF, is used in combination with traditional cytotoxic agents because angiogenesis and tumor cell invasion are closely associated. There have been reports high objective response, and in some cases durable responses in patients with recurrent malignant glioma and treated with the combination of irinotecan and bevacizumab. Lower dose, but prolonged administration, of cytotoxic chemotherapy may be an ideal treatment regimen to combine with bevacizumab, and for malignant brain tumors, temozolomide may be the ideal agent, with nearly 100% oral bioavailability and an excellent toxicity profile, permitting prolonged use. We plan to test the hypothesis that combining bevacizumab and temozolomide will target angiogenesis, specifically tumor-related endothelial cells that are unlikely to be temozolomide resistant.

		Treatment Type:		Chemotherapy Immunological, Biological or Targeted Therapy.

		Contact:		MD Anderson Cancer Center Jan Esenwein Program Coordinator, Brain Tumor Program Contact: Jan Esenwein or Marie Woodward 1515 Holcombe Blvd Houston, TX 77030- Phone:(713)745-2264 Fax: (713)794-4999 Click here to send an email Website: www.mdanderson.org/diseases/braincancer/

Translate this pageMicrosoftÂ® Translator

Copyright (c) 1993 - 2009 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740

Website Design By